BPH with Prostatic Enlargement: Next-Line Protocol When Medical Therapy Has Not Met Its Targets

This protocol is for patients with benign prostatic hyperplasia and confirmed prostatic enlargement in whom a prior course of medical therapy failed to achieve the expected improvement in symptom score or reduction in prostate size.

Patient Scenario

Prostatic enlargement is established by at least one of the following: prostate volume greater than 30 g on imaging, prostate-specific antigen (PSA) greater than 1.5 ng/mL, or palpable enlargement detected on digital rectal examination.

Previous Line — Why Escalation Is Triggered

The prior treatment — a 5-alpha reductase inhibitor (as monotherapy or in combination with an alpha blocker or tadalafil) — did not achieve an IPSS decrease of more than 3 points from baseline, or a prostate volume reduction of 15–25% at 6 months. Failure to reach either of these targets triggers escalation to this protocol.

Treatment Approach (partial overview)

The next step centres on surgical intervention. The protocol specifies which procedure is appropriate based on prostate volume and anatomical factors — the complete decision algorithm, including all applicable options and their eligibility criteria, is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000003698

5-ARI monotherapy should be used as a treatment option in patients with LUTS/BPH with prostatic enlargement as judged by a prostate volume of > 30g on imaging, a prostate specific antigen (PSA) > 1.5ng/mL, or palpable prostate enlargement on digital rectal exam (DRE).

5-ARI in combination with an alpha blocker should be offered as a treatment option only to patients with LUTS associated with demonstrable prostatic enlargement as judged by a prostate volume of > 30g on imaging, a PSA > 1.5ng/mL, or palpable prostate enlargement on DRE.

TURP should be offered as a treatment option for patients with LUTS/BPH.

TUIP should be offered as an option for patients with prostates ≤30g for the surgical treatment of LUTS/BPH.

PVP should be offered as an option using 120W or 180W platforms for the treatment of LUTS/BPH.

Holmium laser enucleation of the prostate (HoLEP) or thulium laser enucleation of the prostate (ThuLEP) should be considered as an option, depending on the clinician's expertise with these techniques, as prostate size-independent options for the treatment of LUTS/BPH.

Bipolar TUVP may be offered as an option to patients for the treatment of LUTS/BPH.

PUL should be considered as a treatment option for patients with LUTS/BPH provided prostate volume 30–80g and verified absence of an obstructive middle lobe.

WVTT should be considered as a treatment option for patients with LUTS/BPH provided prostate volume 30–80g.

Robotic waterjet treatment (RWT) may be offered as a treatment option to patients with LUTS/BPH provided prostate volume 30–80g.

Open, laparoscopic, or robotic assisted prostatectomy should be considered as treatment options by clinicians, depending on their expertise with these techniques, only in patients with large to very large prostates.

PAE may be offered for the treatment of LUTS/BPH.

TIPD may be offered as a treatment option for patients with LUTS/BPH provided prostate volume is between 25 and 75g and lack of obstructive median lobe.

View source ↗